Pharmacokinetics, safety, and overall response rate achieved with subcutaneous administration of rituximab in combination with chemotherapy were comparable with those achieved with intravenous administration in patients with follicular lymphoma in the first-line setting: stage 1 results of the phase 3 SABRINA study (BO22334) - Davies, A; Merli, F; Mihaljevic, B (Blood (ASH Annual Meeting Abstracts), 2012)
et al.